Minimal residual disease negativity was achieved at a significantly higher rate with venetoclax-based therapies, supporting its role in CLL.

随着癌症免疫疗法的不断发展，如何平衡疗效与副作用成为了一个亟待解决的问题。本文研究发现为科学家们提供了一个新的视角，让他们看到了通过精准预测和干预来优化治疗方案的可能性。未来随着更多类似的研究成果涌现，我们有理由相信，癌症治疗将变得更加个性化、安全和 ...

B-cell acute lymphoblastic leukemia (B-ALL) is a life-threatening and highly aggressive form of blood cancer. It is the most ...

Jan. 16, 2025 — Two new studies have identified a possible way to block the progression of several forms of blood cancer using a drug already in clinical trials ... New Innovative Local ...

The global leukemia therapeutics treatment market is expected to grow at a CAGR of 6.6% during the forecast period (2025–2035). Factors such as the rising prevalence of leukemia, increasing adoption ...

ABL1 digital PCR can reliably quantify stable deep molecular remission of chronic myeloid leukemia (CML), which will help to ...

Researchers at the University of Houston, in collaboration with Baylor College of Medicine, are developing new devices for ...

Pediatric patients with ALL were found to experience deficits in their motor skills between at least 1 month and 4 years after completing treatment.

ABL1 digital PCR can reliably quantify stable deep molecular remission of chronic myeloid leukemia (CML), which will help to determine for which patients chronic drug treatment could potentially be ...

Managing diabetes and chronic lymphocytic leukemia is challenging, but with proactive care, mindfulness and diet changes, I'm ...

ABL1 digital PCR can reliably quantify stable deep molecular remission of chronic myeloid leukemia (CML), which will help to determine for which patients chronic drug treatment could potentially be ...